Peloton Wealth Strategists Increases Position in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Peloton Wealth Strategists has increased its stake in Vertex Pharmaceuticals by 31.8%, now owning a total of 7,954 shares, which accounts for approximately 1.6% of their total investments.
• Several institutional investors, including Activest Wealth Management and Clal Insurance Enterprises Holdings, have recently modified their holdings, indicating growing interest in Vertex Pharmaceuticals.
• Vertex Pharmaceuticals reported a quarterly earnings per share of $4.52, surpassing estimates, with a net margin of 31.86% and annual revenue growth of 11.3%.

Peloton Wealth Strategists grew its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 31.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,954 shares of the pharmaceutical company's stock after purchasing an additional 1,920 shares during the period. Vertex Pharmaceuticals makes up about 1.6% of Peloton Wealth Strategists' portfolio, making the stock its 21st biggest position. Peloton Wealth Strategists' holdings in Vertex Pharmaceuticals were worth $3,856,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Quent Capital LLC boosted its position in Vertex Pharmaceuticals by 4.5% during the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company's stock worth $249,000 after purchasing an additional 22 shares in the last quarter. Advisor OS LLC boosted its position in Vertex Pharmaceuticals by 4.4% during the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company's stock worth $263,000 after purchasing an additional 23 shares in the last quarter. Sculati Wealth Management LLC boosted its position in Vertex Pharmaceuticals by 1.0% during the fourth quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company's stock worth $1,029,000 after purchasing an additional 25 shares in the last quarter. Avidian Wealth Enterprises LLC boosted its position in Vertex Pharmaceuticals by 2.1% during the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company's stock worth $594,000 after purchasing an additional 25 shares in the last quarter. Finally, Strategic Blueprint LLC boosted its position in Vertex Pharmaceuticals by 1.7% during the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company's stock worth $726,000 after purchasing an additional 25 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock traded up $8.82 during trading on Thursday, reaching $397.37. 1,329,815 shares of the company were exchanged, compared to its average volume of 1,405,562. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The company has a market capitalization of $101.88 billion, a P/E ratio of 28.40 and a beta of 0.44. The stock's 50 day simple moving average is $423.87 and its two-hundred day simple moving average is $454.15.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter last year, the business posted ($12.83) earnings per share. The firm's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Royal Bank Of Canada lowered their price target on Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating on the stock in a research report on Tuesday, August 5th. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 price target on the stock in a research report on Wednesday, August 6th. HC Wainwright decreased their target price on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a research report on Tuesday, August 5th. Scotiabank decreased their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating on the stock in a research report on Tuesday, August 5th. Finally, Morgan Stanley set a $439.00 target price on Vertex Pharmaceuticals and gave the company an "equal weight" rating in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $496.05.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was bought at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.